Boston Scientific Corporation
BSX
$101.49
$2.572.59%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 12.08% | -6.94% | 20.37% | 57.32% | 260.71% |
| Total Depreciation and Amortization | 11.18% | 2.00% | 4.36% | 6.67% | 6.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.22% | -12.86% | 271.15% | -4.39% | 402.56% |
| Change in Net Operating Assets | 668.42% | 194.32% | -1,392.86% | -42.07% | -117.07% |
| Cash from Operations | 52.14% | 43.55% | 23.56% | -13.68% | 18.59% |
| Capital Expenditure | -3.75% | 5.79% | -8.39% | -61.26% | -25.94% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -66.67% | -100.00% |
| Cash Acquisitions | -331.02% | -- | 92.53% | 87.47% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -257.14% | -1,412.50% | -25.93% | -5,900.00% | -68.18% |
| Cash from Investing | -251.76% | -624.37% | 67.74% | 41.12% | -475.41% |
| Total Debt Issued | -- | 159.46% | -100.00% | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | 64.71% | 28.00% | -3.70% | 26.98% | -10.53% |
| Repurchase of Common Stock | -55.36% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | 100.00% |
| Other Financing Activities | 55.56% | -516.67% | 71.43% | -7.63% | 1,180.00% |
| Cash from Financing | 1,326.67% | -56.25% | -44.19% | 2,373.91% | 1,400.00% |
| Foreign Exchange rate Adjustments | -325.00% | 220.00% | 66.67% | -- | 33.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,554.55% | -180.31% | 495.10% | 496.97% | -112.24% |